Clinical trial · Observational
Feasibility of Immunotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home Setting (ImHADom)
Feasibility of Immunotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home Setting - ImHADom
NCT03786653CI-TRIAL-00094961ImHADomcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational prospective monosite study aims to describe, for the first time, management in a hospital-at-home programme of patients treated by immunotherapy for bronchial cancer. The feasibility in good conditions of this management, the patients' quality of life and their satisfaction will be evaluated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bronchial Cancer | Bronchogenic Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Feasibility of home-based immunotherapy (percentage of patients who interrupted their home hospitalization for reasons directly linked to that management)
- timeFrame
- 1 year
- description
- Feasibility under good conditions of home-based immunotherapy, defined by the percentage of patients who interrupted their home hospitalization for reasons directly linked to that management.
Secondary outcomes (4)
- measure
- adverse effects
- timeFrame
- 1 year
- description
- Immunotherapy related adverse effects monitoring criteria evaluation
- measure
- Number of Incidents occurring during the Hospital at Home program handling process
- timeFrame
- 1 year
- description
- The occurrence of possible incidents related to the Hospital at Home program will be collected at each home based hospitalization.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged 18 and over. * with bronchial cancer treated with immunotherapy, * having two assessments of the response to immunotherapy received in day hospitalization with efficiency (stability or partial response) * without any graded higher than 1 adverse effects, or uncontrolled grade 1 adverse effects related to immunotherapy * eligible for a home-based hospitalization Exclusion Criteria: * Patient receiving immunotherapy via temporary authorization for use, * Frail patients requiring a frequent medical assessment thus day hospitalization cares
References
Publications (0)
Data not yet available
No reference posted for this study.